ATE406897T1 - Kombination von et-743 mit 5-fluorouracil pro- drugs zur behandlung von krebs - Google Patents
Kombination von et-743 mit 5-fluorouracil pro- drugs zur behandlung von krebsInfo
- Publication number
- ATE406897T1 ATE406897T1 AT04798717T AT04798717T ATE406897T1 AT E406897 T1 ATE406897 T1 AT E406897T1 AT 04798717 T AT04798717 T AT 04798717T AT 04798717 T AT04798717 T AT 04798717T AT E406897 T1 ATE406897 T1 AT E406897T1
- Authority
- AT
- Austria
- Prior art keywords
- combination
- cancer
- drugs
- treatment
- fluorouracil
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51969003P | 2003-11-13 | 2003-11-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE406897T1 true ATE406897T1 (de) | 2008-09-15 |
Family
ID=34619369
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT04798717T ATE406897T1 (de) | 2003-11-13 | 2004-11-15 | Kombination von et-743 mit 5-fluorouracil pro- drugs zur behandlung von krebs |
Country Status (15)
Country | Link |
---|---|
US (1) | US7622458B2 (de) |
EP (1) | EP1689404B9 (de) |
JP (1) | JP2007511499A (de) |
AT (1) | ATE406897T1 (de) |
CA (1) | CA2544320A1 (de) |
CY (1) | CY1108629T1 (de) |
DE (1) | DE602004016376D1 (de) |
DK (1) | DK1689404T3 (de) |
ES (1) | ES2314470T3 (de) |
HR (1) | HRP20080598T3 (de) |
PL (1) | PL1689404T3 (de) |
PT (1) | PT1689404E (de) |
RS (1) | RS50692B (de) |
SI (1) | SI1689404T1 (de) |
WO (1) | WO2005049031A1 (de) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY164077A (en) | 1999-05-13 | 2017-11-30 | Pharma Mar Sa | Compositions and uses of et743 for treating cancer |
MXPA02011319A (es) | 2000-05-15 | 2003-06-06 | Pharma Mar Sa | Analogos antitumorales de ecteinascidina 743. |
CA2428160C (en) * | 2000-11-06 | 2009-10-13 | Pharma Mar, S.A. | Compositions for antitumor treatment containing ecteinascidin 743 |
GB0117402D0 (en) * | 2001-07-17 | 2001-09-05 | Pharma Mar Sa | New antitumoral derivatives of et-743 |
GB0202544D0 (en) | 2002-02-04 | 2002-03-20 | Pharma Mar Sa | The synthesis of naturally occuring ecteinascidins and related compounds |
GB0312407D0 (en) * | 2003-05-29 | 2003-07-02 | Pharma Mar Sau | Treatment |
CA2544320A1 (en) | 2003-11-13 | 2005-06-02 | Pharma Mar, S.A.U. | Method of treating cancer using a combination comprising et-743 and 5-fluorouracil |
US20080255132A1 (en) * | 2003-11-14 | 2008-10-16 | Eric Rowinsky | Combination Therapy Comprising the Use of Et-743 and Paclitaxel for Treating Cancer |
PL1827500T3 (pl) * | 2004-10-26 | 2009-09-30 | Pharma Mar Sa | Pegylowana liposomalna doksorubicyna w kombinacji z ekteinascydyną 743 |
ES2290844T3 (es) | 2004-10-29 | 2008-02-16 | Pharma Mar S.A., Sociedad Unipersonal | Composiciones que comprenden ecteinascidinas y un disacarido. |
EP1906977B1 (de) * | 2005-07-21 | 2012-02-22 | Nuvo Research AG | Stabilisierte chlorit-lösungen in kombination mit fluorpyrimidinen zur krebsbehandlung |
GB0522082D0 (en) * | 2005-10-31 | 2005-12-07 | Pharma Mar Sa | Formulations |
AU2008313634A1 (en) * | 2007-10-19 | 2009-04-23 | Pharma Mar, S.A. | Prognostic molecular markers for ET-743 treatment |
ES2790414T3 (es) | 2010-11-12 | 2020-10-27 | Pharma Mar Sa | Terapia de combinación con un inhibidor de topoisomerasa |
JOP20190254A1 (ar) | 2017-04-27 | 2019-10-27 | Pharma Mar Sa | مركبات مضادة للأورام |
US20210379095A1 (en) * | 2018-02-12 | 2021-12-09 | Array Biopharma Inc. | Methods and Combination Therapy to Treat Biliary Tract Cancer |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5149804A (en) * | 1990-11-30 | 1992-09-22 | The Board Of Trustees Of The University Of Illinois | Ecteinascidins 736 and 722 |
US5256663A (en) * | 1986-06-09 | 1993-10-26 | The Board Of Trustees Of The University Of Illinois | Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith |
US5089273A (en) * | 1986-06-09 | 1992-02-18 | Board Of Trustees Of The University Of Illinois | Ecteinascidins 729, 743, 745, 759A, 759B and 770 |
DE3635711A1 (de) * | 1986-10-21 | 1988-04-28 | Knoll Ag | 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung |
FR2697752B1 (fr) * | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Compositions antitumorales contenant des dérivés du taxane. |
AU671491B2 (en) * | 1992-12-18 | 1996-08-29 | F. Hoffmann-La Roche Ag | N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines |
US5478932A (en) * | 1993-12-02 | 1995-12-26 | The Board Of Trustees Of The University Of Illinois | Ecteinascidins |
US20040059112A1 (en) * | 1994-02-18 | 2004-03-25 | Rinehart Kenneth L. | Ecteinascidins |
GB9508195D0 (en) * | 1995-04-20 | 1995-06-07 | Univ British Columbia | Novel biologically active compounds and compositions,their use and derivation |
US5721362A (en) * | 1996-09-18 | 1998-02-24 | President And Fellows Of Harvard College | Process for producing ecteinascidin compounds |
US5985876A (en) * | 1997-04-15 | 1999-11-16 | Univ Illinois | Nucleophile substituted ecteinascidins and N-oxide ecteinascidins |
BR9909488B1 (pt) | 1998-04-06 | 2011-02-08 | ecteinascidinas semi-sintéticas e composição farmacêutica. | |
AU759281B2 (en) | 1998-05-11 | 2003-04-10 | Pharma Mar S.A. | Metabolites of ecteinascidin 743 |
MY164077A (en) * | 1999-05-13 | 2017-11-30 | Pharma Mar Sa | Compositions and uses of et743 for treating cancer |
AR035842A1 (es) | 1999-05-14 | 2004-07-21 | Pharma Mar Sa | Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo |
CZ298259B6 (cs) * | 2000-02-28 | 2007-08-08 | Aventis Pharma S. A. | Farmaceutická kombinace k lécení rakoviny obsahující CPT-11 a capecitabin |
SI1280809T1 (sl) | 2000-04-12 | 2005-12-31 | Pharma Mar Sa | Antitumorski ekteinascidin derivati |
CA2418320A1 (en) * | 2000-08-11 | 2002-02-21 | City Of Hope | The anti-neoplastic agent et-743 inhibits trans activation by sxr |
CA2428160C (en) | 2000-11-06 | 2009-10-13 | Pharma Mar, S.A. | Compositions for antitumor treatment containing ecteinascidin 743 |
EP1360337A1 (de) | 2001-02-09 | 2003-11-12 | The Regents Of The University Of California | Mitglieder der ecteinascidin familie: zusammensetzungen und methoden |
GB0121285D0 (en) | 2001-09-03 | 2001-10-24 | Cancer Res Ventures Ltd | Anti-cancer combinations |
JP2005509650A (ja) * | 2001-10-19 | 2005-04-14 | ファルマ・マール・ソシエダード・アノニマ | 癌治療における抗腫瘍化合物の改良した使用 |
US20040019027A1 (en) * | 2002-04-12 | 2004-01-29 | Barry Forman | Method of treating cerebrotendinous xanthomatosis |
GB0312407D0 (en) * | 2003-05-29 | 2003-07-02 | Pharma Mar Sau | Treatment |
GB0324201D0 (en) * | 2003-10-15 | 2003-11-19 | Pharma Mar Sau | Improved antitumoral combinations |
CA2544320A1 (en) | 2003-11-13 | 2005-06-02 | Pharma Mar, S.A.U. | Method of treating cancer using a combination comprising et-743 and 5-fluorouracil |
US20080255132A1 (en) | 2003-11-14 | 2008-10-16 | Eric Rowinsky | Combination Therapy Comprising the Use of Et-743 and Paclitaxel for Treating Cancer |
GB0326486D0 (en) * | 2003-11-14 | 2003-12-17 | Pharma Mar Sau | Combination treatment |
AU2005288696A1 (en) | 2004-09-28 | 2006-04-06 | Pharma Mar S.A., Sociedad Unipersonal | Ecteinascidin compounds as anti -inflammatory agents |
PL1827500T3 (pl) | 2004-10-26 | 2009-09-30 | Pharma Mar Sa | Pegylowana liposomalna doksorubicyna w kombinacji z ekteinascydyną 743 |
ES2290844T3 (es) * | 2004-10-29 | 2008-02-16 | Pharma Mar S.A., Sociedad Unipersonal | Composiciones que comprenden ecteinascidinas y un disacarido. |
-
2004
- 2004-11-15 CA CA002544320A patent/CA2544320A1/en not_active Abandoned
- 2004-11-15 DK DK04798717T patent/DK1689404T3/da active
- 2004-11-15 DE DE602004016376T patent/DE602004016376D1/de active Active
- 2004-11-15 WO PCT/GB2004/050026 patent/WO2005049031A1/en active Application Filing
- 2004-11-15 ES ES04798717T patent/ES2314470T3/es active Active
- 2004-11-15 PL PL04798717T patent/PL1689404T3/pl unknown
- 2004-11-15 SI SI200430928T patent/SI1689404T1/sl unknown
- 2004-11-15 JP JP2006538970A patent/JP2007511499A/ja active Pending
- 2004-11-15 AT AT04798717T patent/ATE406897T1/de active
- 2004-11-15 US US10/579,160 patent/US7622458B2/en not_active Expired - Fee Related
- 2004-11-15 EP EP04798717A patent/EP1689404B9/de active Active
- 2004-11-15 PT PT04798717T patent/PT1689404E/pt unknown
- 2004-11-15 RS RSP-2008/0567A patent/RS50692B/sr unknown
-
2008
- 2008-12-02 CY CY20081101393T patent/CY1108629T1/el unknown
- 2008-12-02 HR HR20080598T patent/HRP20080598T3/xx unknown
Also Published As
Publication number | Publication date |
---|---|
US20070190164A1 (en) | 2007-08-16 |
CY1108629T1 (el) | 2014-04-09 |
HRP20080598T3 (en) | 2009-01-31 |
DK1689404T3 (da) | 2009-01-26 |
EP1689404B9 (de) | 2009-04-22 |
PT1689404E (pt) | 2008-12-15 |
JP2007511499A (ja) | 2007-05-10 |
US7622458B2 (en) | 2009-11-24 |
DE602004016376D1 (de) | 2008-10-16 |
CA2544320A1 (en) | 2005-06-02 |
WO2005049031A1 (en) | 2005-06-02 |
EP1689404A1 (de) | 2006-08-16 |
PL1689404T3 (pl) | 2009-02-27 |
EP1689404B1 (de) | 2008-09-03 |
SI1689404T1 (sl) | 2009-02-28 |
ES2314470T3 (es) | 2009-03-16 |
RS50692B (sr) | 2010-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1108629T1 (el) | Συνδυασμος ετ 743 με 5 φθοριοουρακιλο προ-φαρμακα δια την θεραπευτικη αγωγη του καρκικου | |
TW200518752A (en) | Combinations of drugs for the treatment of neoplasms | |
ATE399553T1 (de) | Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen | |
CY1106601T1 (el) | Χρηση του παραγωγου κουιναζολινης zd6474 συνδυασμενου με γκεμσιταμπινη και προαιρετικα με ιοντιζουσα ακτινοβολια στη θεραπεια του καρκινου | |
DE60037394D1 (de) | VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE | |
ATE302003T1 (de) | Zubereitungen enthaltend apomorphin und sildenafil und ihre verwendung zur behandlung von erektiler dysfunktion | |
CY1105818T1 (el) | Χρησεις του et743 στην θepαπευτικη αγωγη του καρκινου | |
CY1106259T1 (el) | Συνδυασμενη θepαπεια που πepιλαμβανει zd6474 κι ενα ταξανιο | |
WO2004006842A3 (en) | Combinations of drugs for the treatment of neoplasms | |
BRPI0516024A (pt) | uso de azd 2171 ou de um sal farmaceuticamente aceitável do mesmo e de imatinib, composição farmacêutica, kit, e, método para a produção de um efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente | |
NO20032027L (no) | Effektive antitumorbehandlinger | |
JP2006500346A5 (de) | ||
BR0313117A (pt) | Método para a produção de um efeito redutor de permeabilidade vascular e/ou antiangiogênico em um animal de sangue quente tal como um humano, método para o tratamento de um câncer em um animal de sangue quente tal como um humano, composição farmacêutica, kit, e, uso de zd6474 ou de um seu sal farmaceuticamente aceitável e de zd1839 ou de um seu sal farmaceuticamente aceitável | |
BRPI0508982A (pt) | uso de azd2171 ou de um sal deste farmaceuticamente aceitável excluindo um sal de maleato de azd2171, composição farmacêutica, kit, método para o tratamento de um cáncer em um animal de sangue quente tal como um ser humano, e, uso de sal de maleato de azd2171 e 5 - fu e cpt - 11 | |
ATE427746T1 (de) | 5-methylindirubin zur verwendung in der behandlung von menschlichen festen tumoren | |
DE60116075D1 (de) | Behandlung von tumoren mit photodynamischer therapie | |
MXPA00010254A (es) | Tratamiento de disfuncion sexual en ciertos grupos de pacientes. | |
DE60216292D1 (de) | Calciumtrifluoracetat mit zytotoxischer wirkung | |
DE602004016754D1 (de) | Kombinationstherapie gegen krebserkrankungen mit azd2171 und zd1839 | |
WO2022271810A3 (en) | Bicyclic peptidyl pan-ras inhibitors | |
ATE385798T1 (de) | Pharmazeutische zubereitungen enthaltend azd 2171 und zd 6126 und verwendungen | |
ATE537838T1 (de) | Kombinationstherapie mit kloretazin(tm) | |
MXPA05013827A (es) | Composiciones que comprenden zd6126 junto con 5-fu, cpt-11 o 5-fu y cpt-11, que tienen actividad de dano vascular, para tratar cancer colorectal e. g. | |
ATE339209T1 (de) | Kombinationstherapie mit gemzitabin und zd6126 | |
JP2005161000A (ja) | パターン湿布 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1689404 Country of ref document: EP |